FINANCING
Who is raising money: selling new shares, filing room to sell more later, or borrowing. New shares give every holder a smaller slice.
Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing
Key
Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing
Newest first. A company with several filings is one row; open it for each.
- FDUSFidus Investment CorporationAt-the-market programme, with Raymond James & Associates$400.0M55% of value−6.6%424B3 ↗
- VSTMVerastem, Inc.At-the-market programme, with Cantor Fitzgerald$100.0M13% of value−32.5%S-3ASR ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−50.3%S-3 ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−50.3%424B5 ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−50.3%8-K ↗
- AVTXAvalo Therapeutics, Inc.At-the-market programme$200.0M51% of value−4.4%8-K ↗
- AVTXAvalo Therapeutics, Inc.At-the-market programme, with Jefferies$200.0M51% of value−4.4%424B5 ↗
- DDD3D Systems CorporationAt-the-market programme, with Cantor Fitzgerald$42.5M17% of value−48.9%8-K ↗
- DDD3D Systems CorporationAt-the-market programme$42.5M17% of value−48.9%424B5 ↗
- BIVIBioVie Inc.At-the-market programme$1.2M14% of value−40.3%424B5 ↗
- BIVIBioVie Inc.At-the-market programme$6.5M75% of value−53.8%424B5 ↗
- QNRXQuoin Pharmaceuticals, Ltd.At-the-market programme, with Leerink Partners$11.0M70% of value−18.4%424B5 ↗
- DSGNDesign Therapeutics, Inc.At-the-market programme$200.0M35% of value−15.1%424B5 ↗
- ARVNArvinas, Inc.At-the-market programme, with Piper Sandler$200.0M47% of value−8.9%S-3 ↗
- OCSOculis Holding AGAt-the-market programme, with Leerink Partners$100.0M25% of value−7.5%424B5 ↗
- CSWCCapital Southwest CorporationAt-the-market programme, with RBC Capital Markets$2.00B1.3x value−3.7%424B3 ↗
- MSTRStrategy IncAt-the-market programme$21.00B64% of value−40.4%424B5 ↗
- MSTRStrategy IncAt-the-market programme$1.66B5.0% of value−40.4%424B5 ↗
- MSTRStrategy IncAt-the-market programme$2.10B6.4% of value−40.4%424B5 ↗
- MSTRStrategy IncAt-the-market programme$4.13B13% of value−40.4%424B5 ↗
- BLNKBlink Charging Co.At-the-market programme, with H.C. Wainwright$100.0M2.1x value−19.5%S-3 ↗
- APVOAptevo Therapeutics Inc.At-the-market programme$2.3M1.6x value−69.8%424B5 ↗
- XELXcel Energy Inc.At-the-market programme, with Barclays Capital$6.00B12% of value−0.7%424B5 ↗
- PLDPrologis, Inc.At-the-market programme, with BTIG$5.00B4.2% of value−4.3%424B5 ↗
- VORVor Biopharma Inc.At-the-market programme, with William Blair$150.0M13% of value−8.2%424B5 ↗
- PROKProKidney Corp.At-the-market programme$200.0M48% of value−29.3%8-K ↗
- PROKProKidney Corp.At-the-market programme, with Jefferies$200.0M48% of value−29.3%S-3 ↗
- BFLYButterfly Network, Inc.At-the-market programme, with TD Securities (USA)$150.0M10% of value−30.9%S-3ASR ↗
- EQIXEquinix, Inc.At-the-market programme, with Barclays Capital$700.0M0.7% of value−3.4%S-3ASR ↗
- AURAurora Innovation, Inc.At-the-market programme$1.17B17% of value−31.1%424B5 ↗
- CTOCTO Realty Growth, Inc.At-the-market programme, with BofA Securities$89.5M12% of value+3.2%424B5 ↗
- OSSOne Stop Systems, Inc.At-the-market programme, with Piper Sandler$50.0M50% of value−40.7%8-K ↗
- OSSOne Stop Systems, Inc.At-the-market programme, with Piper Sandler$50.0M50% of value−40.7%424B5 ↗
- XXII22nd Century Group, Inc.At-the-market programme, with Needham$18.8M−94.5%424B5 ↗
- XXII22nd Century Group, Inc.At-the-market programme, with Needham$18.8M−97.1%424B5 ↗
- ZURAZura Bio LimitedAt-the-market programme, with Leerink Partners$114.0M1.3x value−78.2%S-3 ↗
- PBKPowerBank CorporationAt-the-market programme$200.0M−48.0%F-3 ↗
- ASSTStrive, Inc.At-the-market programme, with Cantor Fitzgerald$1.00B54% of value−49.9%424B5 ↗
- EARNEllington Credit CompanyAt-the-market programme, with Citizens JMP Securities$125.0M1.3x value−31.0%424B3 ↗
- XPONExpion Energy, Inc.At-the-market programme, with H.C. Wainwright$1.7M84% of value−50.1%S-3 ↗
- IMRNImmuron LimitedAt-the-market programme$2.0M28% of value−5.6%424B5 ↗
- TRAWTraws Pharma, Inc.Equity line with Roth Principal Investments$50.0M−48.5%8-K ↗
- PINEAlpine Income Property Trust, Inc.At-the-market programme$150.0M51% of value+0.7%424B5 ↗
- PINEAlpine Income Property Trust, Inc.At-the-market programme$35.0M12% of value+0.7%424B5 ↗
- AXGSolowin HoldingsAt-the-market programme, with Chaince Securities$50.0M−95.0%424B5 ↗
- AEHLAntelope Enterprise Holdings LimitedAt-the-market programme$100.0M78% of value−26.0%424B5 ↗